MOESM6 of pTuneos: prioritizing tumor neoantigens from next-generation sequencing data

Additional file 6: Table S5. A. Candidate neoepitopes identified using pTuneos Pre&RecNeo from MEL_21. B. Candidate neoepitopes identified using pTuneos Pre&RecNeo from MEL_38. C. Candidate neoepitopes identified using pTuneos Pre&RecNeo from MEL_218. D. Candidate neoepitopes identified using MuPeXI from MEL_21 (only retain neoantigen priority score>0). E. Candidate neoepitopes identified using MuPeXI from MEL_38 (only retain neoantigen priority score>0). F. Candidate neoepitopes identified using MuPeXI from MEL_218 (only retain neoantigen priority score>0). G. Candidate neoepitopes identified using neopepsee from MEL_21 (only retain neoantigen predition level is high or medium). H. Candidate neoepitopes identified using neopepsee from MEL_38 (only retain neoantigen predition level is high or medium). I. Candidate neoepitopes identified using neopepsee from MEL_218 (only retain neoantigen predition level is high or medium).

补充文件6：表S5。A. 采用pTuneos Pre&RecNeo从MEL_21中鉴定得到的候选新表位。B. 采用pTuneos Pre&RecNeo从MEL_38中鉴定得到的候选新表位。C. 采用pTuneos Pre&RecNeo从MEL_218中鉴定得到的候选新表位。D. 采用MuPeXI从MEL_21中鉴定得到的候选新表位（仅保留新抗原优先级评分>0的结果）。E. 采用MuPeXI从MEL_38中鉴定得到的候选新表位（仅保留新抗原优先级评分>0的结果）。F. 采用MuPeXI从MEL_218中鉴定得到的候选新表位（仅保留新抗原优先级评分>0的结果）。G. 采用neopepsee从MEL_21中鉴定得到的候选新表位（仅保留新抗原预测等级为高或中等的结果）。H. 采用neopepsee从MEL_38中鉴定得到的候选新表位（仅保留新抗原预测等级为高或中等的结果）。I. 采用neopepsee从MEL_218中鉴定得到的候选新表位（仅保留新抗原预测等级为高或中等的结果）。